

May 18, 2017



A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

NAMUR, Belgium, May 18, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced the publication of a research paper entitled "Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer". The study was published in *Clinical Epigenetics* in collaboration with the CHU UCL Namur, Site de Mont Godinne, Belgium.

Volition's Chief Executive Officer, Cameron Reynolds, commented, "I am delighted that this paper reporting one of our earlier pilot studies has been accepted for peer review publication. To detect colorectal cancer and pre-cancerous polyps with such high accuracy is extremely encouraging, particularly the high early-stage detection. We are focused on using these exciting results to develop our frontline product. Our product development process involves large trials of thousands of patients and extensive assay development work at our new purpose-built facility in Belgium."

The lead author of the paper, Professor Jean-François Rahier, is a gastroenterologist and a recognized member of the Belgian research group on inflammatory diseases BIRD (Belgian IBD Research group) and the European group ECCO (European Crohn and Colitis Organization). Professor Rahier commented, "The development of better methods for the early detection of colorectal cancer is critical for the improvement of patients' survival rates. We have found that a Nu.Q™ panel test detects colorectal cancer and pre-cancer with high accuracy, indicating it may prove to be useful as a routine clinical colorectal cancer blood test."

Our four Nu.Q™ assays demonstrated Colorectal Cancer (CRC) detection accuracy of 74% sensitivity at 90% specificity and detected all stages of the cancer, including 75% of early stage I cancers. The study also showed that by using an age adjusted scoring system the accuracy of CRC detection increased to 91% of cancers at 90% specificity. The study consisted of 58 patients over 50 years of age classified into three groups based on their colonoscopy reports: (i) patients with CRC (n = 23), (ii) patients with polyps (n = 16), and (iii) healthy controls with no endoscopic lesions (n = 19).

The results in early stage cancers showed to be particularly positive in comparison to the current, most commonly used blood test for colorectal cancer, Carcinoembryonic Antigen (CEA). In this study, in comparison to the Nu.Q™ results, the CEA results gave a detection rate of 35% of cancers overall at 90% specificity; however, critically, CEA detected no stage I cancers. Not only did the study show very good early stage detection with Nu.Q™ assays, it also demonstrated high pre-cancer polyp detection, with a different Nu.Q™ panel of four assays detecting 62% of polyps at 90% specificity. These are both extremely encouraging outcomes of the study.

A copy of the full paper can be found on our website at <http://volitionrx.com/downloads>

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics[®], which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition L.day@volitionrx.com +44 (0)7557 774620	Scott Powell, Volition S.powell@volitionrx.com +1 (646) 650 1351
Tirth Patel, Edison Advisors tpatel@edisongroup.com +1 (646) 653 7035	Rachel Carroll, Edison Advisors rcarroll@edisongroup.com +44 (0)20 3077 5711

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/a-new-publication-reports-that-91-of-colorectal-cancers-were-detected-at-90-specificity-in-a-completed-prospective-trial-using-volitions-nuqtm-assays-300459980.html>

SOURCE VolitionRx Ltd.